|
WO2021065027A1
|
|
Dysuria-alleviating agent
|
|
EP3718550A1
|
|
Powder preparation for nasal administration
|
|
EP3725795A1
|
|
Stable-isotope-labeled compound
|
|
WO2019044868A1
|
|
Pyrimidine derivative
|
|
JP2019089560A
|
|
Packing box
|
|
WO2017188222A1
|
|
Medicinal drug containing fenofibrate
|
|
JP2018127434A
|
|
15-oxosteroid compound and method for producing the same
|
|
CN108137513A
|
|
Pyrimidine derivatives
|
|
JP2016094249A
|
|
Packing box
|
|
WO2015064479A1
|
|
Novel levonorgestrel crystal mixture and process for producing same
|
|
WO2014175302A1
|
|
Amorphous levonorgestrel, solid dispersion, and manufacturing method for same
|
|
WO2014175304A1
|
|
β CRYSTALLINE POLYMORPH OF LEVONORGESTREL, AND MANUFACTURING METHOD FOR SAME
|
|
WO2014175303A1
|
|
α CRYSTALLINE POLYMORPH OF LEVONORGESTREL, AND MANUFACTURING METHOD FOR SAME
|
|
TW201522362A
|
|
Crystalline polymorphic form of ulipristal acetate
|
|
TW201522360A
|
|
Crystalline polymorphic form of ulipristal acetate
|
|
TW201522361A
|
|
Amorphous ulipristal acetate
|
|
WO2014050105A1
|
|
Amorphous ulipristal acetate
|
|
CA2885798A1
|
|
Crystalline polymorphic form of ulipristal acetate
|
|
US2015239927A1
|
|
Crystalline polymorphic form of ulipristal acetate
|
|
JP2013047282A
|
|
Fenofibrate-containing composition
|
